Skip to main content
iNtRON Biotechnology, Inc. logo

iNtRON Biotechnology, Inc. — Investor Relations & Filings

Ticker · 048530 ISIN · KR7048530000 KO Manufacturing
Open in API
Filings indexed 268 across all filing types
Latest filing 2022-07-05 Transaction in Own Shar…
Country KR South Korea
Listing KO 048530

About iNtRON Biotechnology, Inc.

https://intronbio.com:6001

iNtRON Biotechnology, Inc. is a biotechnology company specializing in solutions for infectious diseases. Its core activities are centered on three main pillars: bio-new drugs, molecular diagnostics, and molecular biology reagents. The company's therapeutic pipeline focuses on developing novel treatments for drug-resistant super-bacteria, creating antibiotic alternatives and other bio-active agents to address the challenge of antimicrobial resistance (AMR). In its diagnostics division, iNtRON develops and manufactures detection kits and assays, primarily based on real-time PCR technology, for the rapid identification of infectious organisms. The company also provides a range of molecular reagents for research and has commercialized antibiotic alternative products for the animal health market.

Recent filings

Filing Released Lang Actions
주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Supervisory Service in South Korea, specifically detailing the decision to enter into a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 체결 결정). This falls under the category of a company buying back its own shares, which is classified as 'Transaction in Own Shares' (POS).
2022-07-05 Korean
투자판단관련주요경영사항(로이반트 자회사 라이소반트, SAL200 관련 계약 해지)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from Intron Biotechnology regarding a material management decision (the termination of a licensing agreement for SAL200). It details the contract termination, the retention of the upfront payment, and the strategic implications for the company. As this is a specific regulatory disclosure of a material event (a contract termination) that does not fit into categories like M&A, financial reports, or director dealings, it falls under the general regulatory filing category.
2022-06-28 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and details of an Investor Relations (IR) meeting (기업설명회). It provides the date, time, location, purpose, and contact information for the event. Since it is an announcement of an upcoming event rather than the presentation materials themselves, and it serves as a regulatory notification of corporate activity, it fits the definition of a Regulatory Filing (RNS) or a general announcement of corporate events.
2022-06-28 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from Intron Biotechnology regarding the adjustment of the conversion price for its 8th series convertible bonds. This type of disclosure, which details changes to the capital structure (specifically conversion price and number of convertible shares due to market price fluctuations), falls under the category of capital and financing updates.
2022-06-02 Korean
[기재정정]분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the first quarter of 2022, filed by iNtRON Biotechnology. It contains detailed financial data, management discussion, business operations, and capital structure information. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-16 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for iNtRON Biotechnology, Inc. covering the period from January 1, 2022, to March 31, 2022. It contains detailed financial data, business operations, and management information, which is characteristic of an interim financial report. It is not a mere announcement or certification, but the full report itself. Q1 2022
2022-05-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.